Login to Your Account

Money from home: European biotech turns back to home turf

By Cormac Sheridan
Staff Writer

Monday, April 18, 2016

DUBLIN – Even if the U.S. public markets are cooling on European biotech, a clutch of recent transactions suggests that companies' home markets still remain supportive. Financing activity has been sluggish this year, in contrast with last year, but a trickle of cash is still flowing into European biotech.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription